Evogene (EVGN) Other Non-Current Assets (2012 - 2025)
Evogene (EVGN) posted Other Non-Current Assets of $12.2 million for Q2 2025, up 40626.67% sequentially from $30000.0 in Q2 2024, and up 40626.67% YoY from N/an in Q2 2024.
Evogene (EVGN) Other Non-Current Assets (2012 - 2025) Analysis & Trends
Evogene has reported Other Non-Current Assets for 14 years, with the latest figure at $12.2 million in Q2 2025.
- Quarterly Other Non-Current Assets rose 40626.67% year-over-year to $12.2 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $12.2 million (up 40626.67% YoY) and the FY2023 annual result came in at $28000.0, down 62.16% from the prior year.
- Other Non-Current Assets advanced to $12.2 million in Q2 2025 per EVGN's latest filing, from $30000.0 in the prior quarter.
- Over five years, Other Non-Current Assets peaked at $12.2 million in Q2 2025 and troughed at $10000.0 in Q1 2021.
- A 5-year average of $1.0 million and a median of $25000.0 in 2021 frame the typical range for Other Non-Current Assets.
- The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets plunged 62.16% in 2023, then surged 40626.67% in 2025.
- Over 5 years, Other Non-Current Assets stood at $25000.0 in 2021, then surged by 196.0% to $74000.0 in 2022, then slumped by 62.16% to $28000.0 in 2023, then increased by 7.14% to $30000.0 in 2024, then soared by 40626.67% to $12.2 million in 2025.
- According to Business Quant data, Other Non-Current Assets over the past three periods registered $12.2 million, $30000.0, and $28000.0 for Q2 2025, Q2 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | Evogene | 4.38 Mn | 4.38 Mn | 204,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 12.22 Mn |
| Jun 30, 2024 | 30,000.00 |
| Dec 31, 2023 | 28,000.00 |
| Jun 30, 2023 | 53,000.00 |
| Dec 31, 2022 | 74,000.00 |
| Sep 30, 2022 | 21,000.00 |
| Jun 30, 2022 | 24,000.00 |
| Mar 31, 2022 | 25,000.00 |
| Dec 31, 2021 | 25,000.00 |
| Sep 30, 2021 | 25,000.00 |
| Jun 30, 2021 | 12,000.00 |
| Mar 31, 2021 | 10,000.00 |
| Dec 31, 2020 | 9,000.00 |
| Sep 30, 2020 | 9,000.00 |
| Jun 30, 2020 | 9,000.00 |
| Mar 31, 2020 | 9,000.00 |
| Dec 31, 2019 | 9,000.00 |
| Sep 30, 2019 | 8,000.00 |
| Dec 31, 2018 | 19,000.00 |
| Sep 30, 2018 | 21,000.00 |